nodes	percent_of_prediction	percent_of_DWPC	metapath
Tobramycin—Nervous system disorder—Vandetanib—thyroid cancer	0.00311	0.00311	CcSEcCtD
Tobramycin—Thrombocytopenia—Vandetanib—thyroid cancer	0.0031	0.0031	CcSEcCtD
Tobramycin—Skin disorder—Vandetanib—thyroid cancer	0.00308	0.00308	CcSEcCtD
Tobramycin—Laryngitis—Epirubicin—thyroid cancer	0.00307	0.00307	CcSEcCtD
Tobramycin—Haemoptysis—Epirubicin—thyroid cancer	0.00299	0.00299	CcSEcCtD
Tobramycin—Hyperventilation—Doxorubicin—thyroid cancer	0.00298	0.00298	CcSEcCtD
Tobramycin—Urinary tract disorder—Sorafenib—thyroid cancer	0.00297	0.00297	CcSEcCtD
Tobramycin—Connective tissue disorder—Sorafenib—thyroid cancer	0.00296	0.00296	CcSEcCtD
Tobramycin—Urethral disorder—Sorafenib—thyroid cancer	0.00295	0.00295	CcSEcCtD
Tobramycin—Lung disorder—Doxorubicin—thyroid cancer	0.00289	0.00289	CcSEcCtD
Tobramycin—Musculoskeletal discomfort—Vandetanib—thyroid cancer	0.00289	0.00289	CcSEcCtD
Tobramycin—Paraesthesia—Vandetanib—thyroid cancer	0.00284	0.00284	CcSEcCtD
Tobramycin—Laryngitis—Doxorubicin—thyroid cancer	0.00284	0.00284	CcSEcCtD
Tobramycin—Dyspnoea—Vandetanib—thyroid cancer	0.00282	0.00282	CcSEcCtD
Tobramycin—Tinnitus—Sorafenib—thyroid cancer	0.0028	0.0028	CcSEcCtD
Tobramycin—Haemoptysis—Doxorubicin—thyroid cancer	0.00277	0.00277	CcSEcCtD
Tobramycin—Decreased appetite—Vandetanib—thyroid cancer	0.00275	0.00275	CcSEcCtD
Tobramycin—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.00273	0.00273	CcSEcCtD
Tobramycin—Stinging—Epirubicin—thyroid cancer	0.00273	0.00273	CcSEcCtD
Tobramycin—Angiopathy—Sorafenib—thyroid cancer	0.00273	0.00273	CcSEcCtD
Tobramycin—Immune system disorder—Sorafenib—thyroid cancer	0.00272	0.00272	CcSEcCtD
Tobramycin—Injection site pain—Epirubicin—thyroid cancer	0.00271	0.00271	CcSEcCtD
Tobramycin—Mediastinal disorder—Sorafenib—thyroid cancer	0.00271	0.00271	CcSEcCtD
Tobramycin—Pain—Vandetanib—thyroid cancer	0.00271	0.00271	CcSEcCtD
Tobramycin—Dysphonia—Epirubicin—thyroid cancer	0.00269	0.00269	CcSEcCtD
Tobramycin—Erythema—Sorafenib—thyroid cancer	0.00262	0.00262	CcSEcCtD
Tobramycin—Gastrointestinal pain—Vandetanib—thyroid cancer	0.00259	0.00259	CcSEcCtD
Tobramycin—Delirium—Epirubicin—thyroid cancer	0.00257	0.00257	CcSEcCtD
Tobramycin—Dysgeusia—Sorafenib—thyroid cancer	0.00256	0.00256	CcSEcCtD
Tobramycin—Stinging—Doxorubicin—thyroid cancer	0.00253	0.00253	CcSEcCtD
Tobramycin—Injection site pain—Doxorubicin—thyroid cancer	0.00251	0.00251	CcSEcCtD
Tobramycin—Abdominal pain—Vandetanib—thyroid cancer	0.0025	0.0025	CcSEcCtD
Tobramycin—Body temperature increased—Vandetanib—thyroid cancer	0.0025	0.0025	CcSEcCtD
Tobramycin—Dysphonia—Doxorubicin—thyroid cancer	0.00249	0.00249	CcSEcCtD
Tobramycin—Bone disorder—Epirubicin—thyroid cancer	0.00245	0.00245	CcSEcCtD
Tobramycin—Anaemia—Sorafenib—thyroid cancer	0.00242	0.00242	CcSEcCtD
Tobramycin—Hypocalcaemia—Epirubicin—thyroid cancer	0.00242	0.00242	CcSEcCtD
Tobramycin—Cough increased—Epirubicin—thyroid cancer	0.00242	0.00242	CcSEcCtD
Tobramycin—Lacrimation increased—Epirubicin—thyroid cancer	0.0024	0.0024	CcSEcCtD
Tobramycin—Oliguria—Epirubicin—thyroid cancer	0.0024	0.0024	CcSEcCtD
Tobramycin—Angioedema—Sorafenib—thyroid cancer	0.00239	0.00239	CcSEcCtD
Tobramycin—Delirium—Doxorubicin—thyroid cancer	0.00238	0.00238	CcSEcCtD
Tobramycin—Leukopenia—Sorafenib—thyroid cancer	0.00234	0.00234	CcSEcCtD
Tobramycin—Blood bilirubin increased—Epirubicin—thyroid cancer	0.00234	0.00234	CcSEcCtD
Tobramycin—Creatinine increased—Epirubicin—thyroid cancer	0.00233	0.00233	CcSEcCtD
Tobramycin—Cough—Sorafenib—thyroid cancer	0.00228	0.00228	CcSEcCtD
Tobramycin—Asthenia—Vandetanib—thyroid cancer	0.00227	0.00227	CcSEcCtD
Tobramycin—Bone disorder—Doxorubicin—thyroid cancer	0.00227	0.00227	CcSEcCtD
Tobramycin—Pruritus—Vandetanib—thyroid cancer	0.00224	0.00224	CcSEcCtD
Tobramycin—Hypocalcaemia—Doxorubicin—thyroid cancer	0.00224	0.00224	CcSEcCtD
Tobramycin—Cough increased—Doxorubicin—thyroid cancer	0.00224	0.00224	CcSEcCtD
Tobramycin—Myalgia—Sorafenib—thyroid cancer	0.00223	0.00223	CcSEcCtD
Tobramycin—Lacrimation increased—Doxorubicin—thyroid cancer	0.00222	0.00222	CcSEcCtD
Tobramycin—Oliguria—Doxorubicin—thyroid cancer	0.00222	0.00222	CcSEcCtD
Tobramycin—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.00221	0.00221	CcSEcCtD
Tobramycin—Phosphatase alkaline increased—Epirubicin—thyroid cancer	0.00221	0.00221	CcSEcCtD
Tobramycin—Diarrhoea—Vandetanib—thyroid cancer	0.00217	0.00217	CcSEcCtD
Tobramycin—Blood bilirubin increased—Doxorubicin—thyroid cancer	0.00217	0.00217	CcSEcCtD
Tobramycin—Creatinine increased—Doxorubicin—thyroid cancer	0.00215	0.00215	CcSEcCtD
Tobramycin—Anaphylactic shock—Sorafenib—thyroid cancer	0.00214	0.00214	CcSEcCtD
Tobramycin—Nervous system disorder—Sorafenib—thyroid cancer	0.0021	0.0021	CcSEcCtD
Tobramycin—Dizziness—Vandetanib—thyroid cancer	0.00209	0.00209	CcSEcCtD
Tobramycin—Thrombocytopenia—Sorafenib—thyroid cancer	0.00209	0.00209	CcSEcCtD
Tobramycin—Skin disorder—Sorafenib—thyroid cancer	0.00208	0.00208	CcSEcCtD
Tobramycin—Phosphatase alkaline increased—Doxorubicin—thyroid cancer	0.00205	0.00205	CcSEcCtD
Tobramycin—Dry eye—Epirubicin—thyroid cancer	0.00204	0.00204	CcSEcCtD
Tobramycin—Anorexia—Sorafenib—thyroid cancer	0.00204	0.00204	CcSEcCtD
Tobramycin—Vomiting—Vandetanib—thyroid cancer	0.00201	0.00201	CcSEcCtD
Tobramycin—Rash maculo-papular—Epirubicin—thyroid cancer	0.00201	0.00201	CcSEcCtD
Tobramycin—Rash—Vandetanib—thyroid cancer	0.002	0.002	CcSEcCtD
Tobramycin—Dermatitis—Vandetanib—thyroid cancer	0.002	0.002	CcSEcCtD
Tobramycin—Headache—Vandetanib—thyroid cancer	0.00198	0.00198	CcSEcCtD
Tobramycin—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.00195	0.00195	CcSEcCtD
Tobramycin—Dyspnoea—Sorafenib—thyroid cancer	0.0019	0.0019	CcSEcCtD
Tobramycin—Dry eye—Doxorubicin—thyroid cancer	0.00189	0.00189	CcSEcCtD
Tobramycin—Nausea—Vandetanib—thyroid cancer	0.00188	0.00188	CcSEcCtD
Tobramycin—Rash maculo-papular—Doxorubicin—thyroid cancer	0.00186	0.00186	CcSEcCtD
Tobramycin—Decreased appetite—Sorafenib—thyroid cancer	0.00186	0.00186	CcSEcCtD
Tobramycin—Thrombophlebitis—Epirubicin—thyroid cancer	0.00186	0.00186	CcSEcCtD
Tobramycin—Blood alkaline phosphatase increased—Epirubicin—thyroid cancer	0.00185	0.00185	CcSEcCtD
Tobramycin—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.00184	0.00184	CcSEcCtD
Tobramycin—Pain—Sorafenib—thyroid cancer	0.00183	0.00183	CcSEcCtD
Tobramycin—Eye pain—Epirubicin—thyroid cancer	0.00178	0.00178	CcSEcCtD
Tobramycin—Gastrointestinal pain—Sorafenib—thyroid cancer	0.00175	0.00175	CcSEcCtD
Tobramycin—Renal failure acute—Epirubicin—thyroid cancer	0.00174	0.00174	CcSEcCtD
Tobramycin—Thrombophlebitis—Doxorubicin—thyroid cancer	0.00172	0.00172	CcSEcCtD
Tobramycin—Blood alkaline phosphatase increased—Doxorubicin—thyroid cancer	0.00171	0.00171	CcSEcCtD
Tobramycin—Dermatitis exfoliative—Epirubicin—thyroid cancer	0.0017	0.0017	CcSEcCtD
Tobramycin—Urticaria—Sorafenib—thyroid cancer	0.0017	0.0017	CcSEcCtD
Tobramycin—Abdominal pain—Sorafenib—thyroid cancer	0.00169	0.00169	CcSEcCtD
Tobramycin—Body temperature increased—Sorafenib—thyroid cancer	0.00169	0.00169	CcSEcCtD
Tobramycin—Renal impairment—Epirubicin—thyroid cancer	0.00169	0.00169	CcSEcCtD
Tobramycin—Eye pain—Doxorubicin—thyroid cancer	0.00165	0.00165	CcSEcCtD
Tobramycin—Lethargy—Epirubicin—thyroid cancer	0.00164	0.00164	CcSEcCtD
Tobramycin—Renal failure acute—Doxorubicin—thyroid cancer	0.00161	0.00161	CcSEcCtD
Tobramycin—Dermatitis exfoliative—Doxorubicin—thyroid cancer	0.00158	0.00158	CcSEcCtD
Tobramycin—Hypersensitivity—Sorafenib—thyroid cancer	0.00157	0.00157	CcSEcCtD
Tobramycin—Renal impairment—Doxorubicin—thyroid cancer	0.00156	0.00156	CcSEcCtD
Tobramycin—Asthenia—Sorafenib—thyroid cancer	0.00153	0.00153	CcSEcCtD
Tobramycin—Lethargy—Doxorubicin—thyroid cancer	0.00152	0.00152	CcSEcCtD
Tobramycin—Pruritus—Sorafenib—thyroid cancer	0.00151	0.00151	CcSEcCtD
Tobramycin—Blood creatinine increased—Epirubicin—thyroid cancer	0.00151	0.00151	CcSEcCtD
Tobramycin—Dehydration—Epirubicin—thyroid cancer	0.00149	0.00149	CcSEcCtD
Tobramycin—Dry skin—Epirubicin—thyroid cancer	0.00147	0.00147	CcSEcCtD
Tobramycin—Hypokalaemia—Epirubicin—thyroid cancer	0.00146	0.00146	CcSEcCtD
Tobramycin—Diarrhoea—Sorafenib—thyroid cancer	0.00146	0.00146	CcSEcCtD
Tobramycin—Aspartate aminotransferase increased—Epirubicin—thyroid cancer	0.00145	0.00145	CcSEcCtD
Tobramycin—Muscular weakness—Epirubicin—thyroid cancer	0.00142	0.00142	CcSEcCtD
Tobramycin—Dizziness—Sorafenib—thyroid cancer	0.00141	0.00141	CcSEcCtD
Tobramycin—Blood creatinine increased—Doxorubicin—thyroid cancer	0.00139	0.00139	CcSEcCtD
Tobramycin—Asthma—Epirubicin—thyroid cancer	0.00139	0.00139	CcSEcCtD
Tobramycin—Dehydration—Doxorubicin—thyroid cancer	0.00138	0.00138	CcSEcCtD
Tobramycin—Eosinophilia—Epirubicin—thyroid cancer	0.00137	0.00137	CcSEcCtD
Tobramycin—Dry skin—Doxorubicin—thyroid cancer	0.00136	0.00136	CcSEcCtD
Tobramycin—Vomiting—Sorafenib—thyroid cancer	0.00136	0.00136	CcSEcCtD
Tobramycin—Hypokalaemia—Doxorubicin—thyroid cancer	0.00135	0.00135	CcSEcCtD
Tobramycin—Rash—Sorafenib—thyroid cancer	0.00135	0.00135	CcSEcCtD
Tobramycin—Dermatitis—Sorafenib—thyroid cancer	0.00135	0.00135	CcSEcCtD
Tobramycin—Aspartate aminotransferase increased—Doxorubicin—thyroid cancer	0.00134	0.00134	CcSEcCtD
Tobramycin—Headache—Sorafenib—thyroid cancer	0.00134	0.00134	CcSEcCtD
Tobramycin—Bronchitis—Epirubicin—thyroid cancer	0.00134	0.00134	CcSEcCtD
Tobramycin—Muscular weakness—Doxorubicin—thyroid cancer	0.00131	0.00131	CcSEcCtD
Tobramycin—Upper respiratory tract infection—Epirubicin—thyroid cancer	0.00129	0.00129	CcSEcCtD
Tobramycin—Asthma—Doxorubicin—thyroid cancer	0.00128	0.00128	CcSEcCtD
Tobramycin—Eosinophilia—Doxorubicin—thyroid cancer	0.00127	0.00127	CcSEcCtD
Tobramycin—Nausea—Sorafenib—thyroid cancer	0.00127	0.00127	CcSEcCtD
Tobramycin—Weight decreased—Epirubicin—thyroid cancer	0.00126	0.00126	CcSEcCtD
Tobramycin—Infestation NOS—Epirubicin—thyroid cancer	0.00124	0.00124	CcSEcCtD
Tobramycin—Infestation—Epirubicin—thyroid cancer	0.00124	0.00124	CcSEcCtD
Tobramycin—Bronchitis—Doxorubicin—thyroid cancer	0.00124	0.00124	CcSEcCtD
Tobramycin—Renal failure—Epirubicin—thyroid cancer	0.00122	0.00122	CcSEcCtD
Tobramycin—Neuropathy peripheral—Epirubicin—thyroid cancer	0.00121	0.00121	CcSEcCtD
Tobramycin—Stomatitis—Epirubicin—thyroid cancer	0.00121	0.00121	CcSEcCtD
Tobramycin—Upper respiratory tract infection—Doxorubicin—thyroid cancer	0.00119	0.00119	CcSEcCtD
Tobramycin—Epistaxis—Epirubicin—thyroid cancer	0.00117	0.00117	CcSEcCtD
Tobramycin—Weight decreased—Doxorubicin—thyroid cancer	0.00116	0.00116	CcSEcCtD
Tobramycin—Sinusitis—Epirubicin—thyroid cancer	0.00116	0.00116	CcSEcCtD
Tobramycin—Agranulocytosis—Epirubicin—thyroid cancer	0.00116	0.00116	CcSEcCtD
Tobramycin—Infestation—Doxorubicin—thyroid cancer	0.00115	0.00115	CcSEcCtD
Tobramycin—Infestation NOS—Doxorubicin—thyroid cancer	0.00115	0.00115	CcSEcCtD
Tobramycin—Renal failure—Doxorubicin—thyroid cancer	0.00113	0.00113	CcSEcCtD
Tobramycin—Neuropathy peripheral—Doxorubicin—thyroid cancer	0.00112	0.00112	CcSEcCtD
Tobramycin—Stomatitis—Doxorubicin—thyroid cancer	0.00112	0.00112	CcSEcCtD
Tobramycin—Rhinitis—Epirubicin—thyroid cancer	0.00111	0.00111	CcSEcCtD
Tobramycin—Pharyngitis—Epirubicin—thyroid cancer	0.0011	0.0011	CcSEcCtD
Tobramycin—Urinary tract disorder—Epirubicin—thyroid cancer	0.0011	0.0011	CcSEcCtD
Tobramycin—Connective tissue disorder—Epirubicin—thyroid cancer	0.00109	0.00109	CcSEcCtD
Tobramycin—Urethral disorder—Epirubicin—thyroid cancer	0.00109	0.00109	CcSEcCtD
Tobramycin—Epistaxis—Doxorubicin—thyroid cancer	0.00108	0.00108	CcSEcCtD
Tobramycin—Sinusitis—Doxorubicin—thyroid cancer	0.00107	0.00107	CcSEcCtD
Tobramycin—Visual impairment—Epirubicin—thyroid cancer	0.00107	0.00107	CcSEcCtD
Tobramycin—Agranulocytosis—Doxorubicin—thyroid cancer	0.00107	0.00107	CcSEcCtD
Tobramycin—Eye disorder—Epirubicin—thyroid cancer	0.00104	0.00104	CcSEcCtD
Tobramycin—Tinnitus—Epirubicin—thyroid cancer	0.00104	0.00104	CcSEcCtD
Tobramycin—Rhinitis—Doxorubicin—thyroid cancer	0.00103	0.00103	CcSEcCtD
Tobramycin—Pharyngitis—Doxorubicin—thyroid cancer	0.00102	0.00102	CcSEcCtD
Tobramycin—Urinary tract disorder—Doxorubicin—thyroid cancer	0.00102	0.00102	CcSEcCtD
Tobramycin—Connective tissue disorder—Doxorubicin—thyroid cancer	0.00101	0.00101	CcSEcCtD
Tobramycin—Angiopathy—Epirubicin—thyroid cancer	0.00101	0.00101	CcSEcCtD
Tobramycin—Urethral disorder—Doxorubicin—thyroid cancer	0.00101	0.00101	CcSEcCtD
Tobramycin—Immune system disorder—Epirubicin—thyroid cancer	0.001	0.001	CcSEcCtD
Tobramycin—Mediastinal disorder—Epirubicin—thyroid cancer	0.001	0.001	CcSEcCtD
Tobramycin—Visual impairment—Doxorubicin—thyroid cancer	0.000991	0.000991	CcSEcCtD
Tobramycin—Erythema—Epirubicin—thyroid cancer	0.000968	0.000968	CcSEcCtD
Tobramycin—Eye disorder—Doxorubicin—thyroid cancer	0.000961	0.000961	CcSEcCtD
Tobramycin—Tinnitus—Doxorubicin—thyroid cancer	0.000959	0.000959	CcSEcCtD
Tobramycin—Dysgeusia—Epirubicin—thyroid cancer	0.000947	0.000947	CcSEcCtD
Tobramycin—Back pain—Epirubicin—thyroid cancer	0.000936	0.000936	CcSEcCtD
Tobramycin—Angiopathy—Doxorubicin—thyroid cancer	0.000933	0.000933	CcSEcCtD
Tobramycin—Immune system disorder—Doxorubicin—thyroid cancer	0.000929	0.000929	CcSEcCtD
Tobramycin—Mediastinal disorder—Doxorubicin—thyroid cancer	0.000927	0.000927	CcSEcCtD
Tobramycin—Vision blurred—Epirubicin—thyroid cancer	0.000912	0.000912	CcSEcCtD
Tobramycin—Ill-defined disorder—Epirubicin—thyroid cancer	0.000898	0.000898	CcSEcCtD
Tobramycin—Erythema—Doxorubicin—thyroid cancer	0.000895	0.000895	CcSEcCtD
Tobramycin—Anaemia—Epirubicin—thyroid cancer	0.000894	0.000894	CcSEcCtD
Tobramycin—Dysgeusia—Doxorubicin—thyroid cancer	0.000877	0.000877	CcSEcCtD
Tobramycin—Malaise—Epirubicin—thyroid cancer	0.000873	0.000873	CcSEcCtD
Tobramycin—Vertigo—Epirubicin—thyroid cancer	0.000869	0.000869	CcSEcCtD
Tobramycin—Leukopenia—Epirubicin—thyroid cancer	0.000866	0.000866	CcSEcCtD
Tobramycin—Back pain—Doxorubicin—thyroid cancer	0.000866	0.000866	CcSEcCtD
Tobramycin—Cough—Epirubicin—thyroid cancer	0.000844	0.000844	CcSEcCtD
Tobramycin—Vision blurred—Doxorubicin—thyroid cancer	0.000844	0.000844	CcSEcCtD
Tobramycin—Ill-defined disorder—Doxorubicin—thyroid cancer	0.000831	0.000831	CcSEcCtD
Tobramycin—Anaemia—Doxorubicin—thyroid cancer	0.000827	0.000827	CcSEcCtD
Tobramycin—Myalgia—Epirubicin—thyroid cancer	0.000824	0.000824	CcSEcCtD
Tobramycin—Chest pain—Epirubicin—thyroid cancer	0.000824	0.000824	CcSEcCtD
Tobramycin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.000818	0.000818	CcSEcCtD
Tobramycin—Discomfort—Epirubicin—thyroid cancer	0.000814	0.000814	CcSEcCtD
Tobramycin—Malaise—Doxorubicin—thyroid cancer	0.000807	0.000807	CcSEcCtD
Tobramycin—Vertigo—Doxorubicin—thyroid cancer	0.000804	0.000804	CcSEcCtD
Tobramycin—Leukopenia—Doxorubicin—thyroid cancer	0.000801	0.000801	CcSEcCtD
Tobramycin—Confusional state—Epirubicin—thyroid cancer	0.000796	0.000796	CcSEcCtD
Tobramycin—Anaphylactic shock—Epirubicin—thyroid cancer	0.00079	0.00079	CcSEcCtD
Tobramycin—Cough—Doxorubicin—thyroid cancer	0.000781	0.000781	CcSEcCtD
Tobramycin—Nervous system disorder—Epirubicin—thyroid cancer	0.000774	0.000774	CcSEcCtD
Tobramycin—Thrombocytopenia—Epirubicin—thyroid cancer	0.000773	0.000773	CcSEcCtD
Tobramycin—Skin disorder—Epirubicin—thyroid cancer	0.000767	0.000767	CcSEcCtD
Tobramycin—Myalgia—Doxorubicin—thyroid cancer	0.000762	0.000762	CcSEcCtD
Tobramycin—Chest pain—Doxorubicin—thyroid cancer	0.000762	0.000762	CcSEcCtD
Tobramycin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.000757	0.000757	CcSEcCtD
Tobramycin—Discomfort—Doxorubicin—thyroid cancer	0.000753	0.000753	CcSEcCtD
Tobramycin—Anorexia—Epirubicin—thyroid cancer	0.000753	0.000753	CcSEcCtD
Tobramycin—Confusional state—Doxorubicin—thyroid cancer	0.000737	0.000737	CcSEcCtD
Tobramycin—Anaphylactic shock—Doxorubicin—thyroid cancer	0.000731	0.000731	CcSEcCtD
Tobramycin—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.000719	0.000719	CcSEcCtD
Tobramycin—Nervous system disorder—Doxorubicin—thyroid cancer	0.000717	0.000717	CcSEcCtD
Tobramycin—Thrombocytopenia—Doxorubicin—thyroid cancer	0.000715	0.000715	CcSEcCtD
Tobramycin—Skin disorder—Doxorubicin—thyroid cancer	0.00071	0.00071	CcSEcCtD
Tobramycin—Paraesthesia—Epirubicin—thyroid cancer	0.000709	0.000709	CcSEcCtD
Tobramycin—Dyspnoea—Epirubicin—thyroid cancer	0.000704	0.000704	CcSEcCtD
Tobramycin—Anorexia—Doxorubicin—thyroid cancer	0.000696	0.000696	CcSEcCtD
Tobramycin—Decreased appetite—Epirubicin—thyroid cancer	0.000686	0.000686	CcSEcCtD
Tobramycin—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.000682	0.000682	CcSEcCtD
Tobramycin—Pain—Epirubicin—thyroid cancer	0.000675	0.000675	CcSEcCtD
Tobramycin—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.000666	0.000666	CcSEcCtD
Tobramycin—Paraesthesia—Doxorubicin—thyroid cancer	0.000656	0.000656	CcSEcCtD
Tobramycin—Dyspnoea—Doxorubicin—thyroid cancer	0.000651	0.000651	CcSEcCtD
Tobramycin—Feeling abnormal—Epirubicin—thyroid cancer	0.000651	0.000651	CcSEcCtD
Tobramycin—Gastrointestinal pain—Epirubicin—thyroid cancer	0.000646	0.000646	CcSEcCtD
Tobramycin—Decreased appetite—Doxorubicin—thyroid cancer	0.000635	0.000635	CcSEcCtD
Tobramycin—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.000631	0.000631	CcSEcCtD
Tobramycin—Urticaria—Epirubicin—thyroid cancer	0.000627	0.000627	CcSEcCtD
Tobramycin—Pain—Doxorubicin—thyroid cancer	0.000625	0.000625	CcSEcCtD
Tobramycin—Abdominal pain—Epirubicin—thyroid cancer	0.000624	0.000624	CcSEcCtD
Tobramycin—Body temperature increased—Epirubicin—thyroid cancer	0.000624	0.000624	CcSEcCtD
Tobramycin—Feeling abnormal—Doxorubicin—thyroid cancer	0.000602	0.000602	CcSEcCtD
Tobramycin—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.000597	0.000597	CcSEcCtD
Tobramycin—Hypersensitivity—Epirubicin—thyroid cancer	0.000582	0.000582	CcSEcCtD
Tobramycin—Urticaria—Doxorubicin—thyroid cancer	0.00058	0.00058	CcSEcCtD
Tobramycin—Body temperature increased—Doxorubicin—thyroid cancer	0.000578	0.000578	CcSEcCtD
Tobramycin—Abdominal pain—Doxorubicin—thyroid cancer	0.000578	0.000578	CcSEcCtD
Tobramycin—Asthenia—Epirubicin—thyroid cancer	0.000567	0.000567	CcSEcCtD
Tobramycin—Pruritus—Epirubicin—thyroid cancer	0.000559	0.000559	CcSEcCtD
Tobramycin—Diarrhoea—Epirubicin—thyroid cancer	0.00054	0.00054	CcSEcCtD
Tobramycin—Hypersensitivity—Doxorubicin—thyroid cancer	0.000538	0.000538	CcSEcCtD
Tobramycin—Asthenia—Doxorubicin—thyroid cancer	0.000524	0.000524	CcSEcCtD
Tobramycin—Dizziness—Epirubicin—thyroid cancer	0.000522	0.000522	CcSEcCtD
Tobramycin—Pruritus—Doxorubicin—thyroid cancer	0.000517	0.000517	CcSEcCtD
Tobramycin—Vomiting—Epirubicin—thyroid cancer	0.000502	0.000502	CcSEcCtD
Tobramycin—Diarrhoea—Doxorubicin—thyroid cancer	0.0005	0.0005	CcSEcCtD
Tobramycin—Rash—Epirubicin—thyroid cancer	0.000498	0.000498	CcSEcCtD
Tobramycin—Dermatitis—Epirubicin—thyroid cancer	0.000497	0.000497	CcSEcCtD
Tobramycin—Headache—Epirubicin—thyroid cancer	0.000495	0.000495	CcSEcCtD
Tobramycin—Dizziness—Doxorubicin—thyroid cancer	0.000483	0.000483	CcSEcCtD
Tobramycin—Nausea—Epirubicin—thyroid cancer	0.000469	0.000469	CcSEcCtD
Tobramycin—Vomiting—Doxorubicin—thyroid cancer	0.000465	0.000465	CcSEcCtD
Tobramycin—Rash—Doxorubicin—thyroid cancer	0.000461	0.000461	CcSEcCtD
Tobramycin—Dermatitis—Doxorubicin—thyroid cancer	0.00046	0.00046	CcSEcCtD
Tobramycin—Headache—Doxorubicin—thyroid cancer	0.000458	0.000458	CcSEcCtD
Tobramycin—Nausea—Doxorubicin—thyroid cancer	0.000434	0.000434	CcSEcCtD
